Ipamorelin vs GHRP-2

Both of these molecules are GHRPs — synthetic ghrelin-receptor agonists that trigger a pituitary GH pulse — but the comparison most readers come here to make is selectivity. Ipamorelin is the most receptor-selective of the common GHRPs; GHRP-2 is more potent at the GH-release endpoint but pulls cortisol, prolactin, and appetite along with it. The trade is structural: more pulse for more downstream noise, or a quieter pulse with a cleaner side-effect profile.

In a log, that selectivity difference shows up as different fields. Ipamorelin logs typically score the GH pulse signal alone — sleep quality, recovery, the small fasting blood-glucose movements that some readers track. GHRP-2 logs typically also score appetite (the ghrelin-mimetic effect is more pronounced) and an estimated cortisol-pattern proxy via mood and morning energy. Neither molecule needs every field, but choosing the wrong field set during cycle planning makes the data unreadable in retrospect.

Cadence is similar between the two molecules — both are administered two-to-three times daily because both have short half-lives on the order of an hour or two. Per-dose milligrams are also in the same general range (100 mcg ipamorelin and 100–200 mcg GHRP-2 are common per-administration doses), which means the unit count on a 100-unit syringe at the same vial concentration is in the same neighborhood. The mg-to-units calculator linked below handles either once your vial is set.

GH-pulse magnitude is where GHRP-2 has the larger published number, but the more interesting log signal is how well each molecule pairs with a GHRH-side peptide like CJC-1295 or sermorelin. Ipamorelin pairs cleanly because its lack of cortisol or prolactin movement keeps the stack signal isolated to GH. GHRP-2 pairs with a noisier signal, which can be useful when appetite is a desired log variable and unhelpful when it is not.

For the Ipamorelin vs GHRP-2 decision specifically, the calendar shape is what most readers underweight. Ipamorelin's example vial is 2 mg drawn against 0.2 mg per dose at 7 doses per week. GHRP-2's example vial is 5 mg drawn against 0.1 mg per dose at 7 doses per week. Those four numbers feed every column in the table above; change any one and the ipamorelin vs ghrp 2 comparison shifts with it.

Concentration in this pair: Ipamorelin sits at 1.00 mg/mL on the example reconstitution; GHRP-2 sits at 2.50 mg/mL on its example. That single ratio is what determines how many U-100 syringe units a given dose of either molecule actually draws, so it is the first thing to confirm before treating any "Ipamorelin vs GHRP-2" unit number on the internet as authoritative.

Doses per vial in this matchup work out to roughly 10 for Ipamorelin and 50 for GHRP-2 at the example dose sizes, with vial-duration windows near 1.4 weeks and 7.1 weeks respectively. Refill cadence follows directly from those windows, which is why the ipamorelin vs ghrp 2 pair shows up in planning conversations more than in pure mechanism conversations.

When readers compare Ipamorelin against GHRP-2, the Ipamorelin-side mistakes that show up most in logs are: Administering doses at inconsistent times of day, which compromises the ability to observe long-term trends related to its selective action. Logging a combination like Ipamorelin/CJC-1295 as a single dose entry, which inevitably causes errors in vial inventory management for each separate peptide. Misinterpreting the designed absence of an appetite spike as a sign that the peptide is inactive or low in potency. Scheduling administration shortly after a meal containing carbohydrates or fats, thereby blunting the potential GH pulse via insulin release. Each of these gets amplified when a reader is also actively comparing against GHRP-2, because muscle memory from one molecule's unit math leaks into the other.

Ipamorelin question worth answering up front — What is the primary distinction between Ipamorelin and GHRP-6? The defining distinction is selectivity. Ipamorelin was developed specifically to stimulate growth hormone release with high potency while avoiding the significant increases in appetite, cortisol, and prolactin that are characteristic of older secretagogues like GHRP-6. This targeted action results from its refined molecular structure and specific binding profile.

Ipamorelin question worth answering up front — Why is Ipamorelin often studied in combination with CJC-1295 without DAC? This combination is studied because it targets two separate pituitary receptors to synergistically amplify GH release. Ipamorelin acts on the ghrelin receptor while CJC-1295 (no DAC) acts on the GHRH receptor. Activating both pathways at once generates a more robust GH pulse than using either peptide alone, while still honoring the body's natural pulsatile rhythm.

On the GHRP-2 side of the Ipamorelin vs GHRP-2 decision, the recurring mistakes are: Mistaking GHRP-2 for GHRP-6 and failing to account for the documented differences in their side-effect profiles regarding appetite stimulation and prolactin. Neglecting to log the specific time of day for each dose in a multi-dose schedule, which renders later analysis of the data almost meaningless. Using a large-volume syringe (e.g., a 3 mL syringe) that lacks the fine gradations needed to accurately measure a typical 100 mcg dose volume. Administering a dose immediately following a large meal, a variable noted in research that can interfere with the peptide's primary action. These are not generic dosing slips — they are the ones that compound when GHRP-2 is being logged in parallel with Ipamorelin.

GHRP-2 question worth answering up front — How is GHRP-2 structurally different from GHRP-6? GHRP-2 is a synthetic hexapeptide with the sequence D-Ala-D-2-Nal-D-Trp-D-Phe-Lys-NH2. It was developed as a second-generation evolution of GHRP-6. The primary structural difference is the substitution of the natural L-Alanine found in GHRP-6 with a synthetic D-Alanine residue. This single amino acid change significantly alters the molecule’s interaction with the ghrelin receptor, giving rise to its different selectivity profile.

GHRP-2 question worth answering up front — Why do studies describe GHRP-2 as more selective than GHRP-6? In comparative scientific studies, GHRP-2 has been observed to stimulate a potent release of growth hormone while having a lesser impact on cortisol, prolactin, and appetite compared to dose-equivalent administrations of GHRP-6. This means its action is more focused on GH release. While it targets the same ghrelin receptor, its modified structure results in this more specific downstream effect, though it is still considered less selective than the third-generation peptide ipamorelin.